The Impact of Dosing Interval in a Novel Tandem Oral Dosing Strategy: Enhancing the Exposure of Low Solubility Drug Candidates in a Preclinical Setting

Table 2

Exposure of Compound 2 from s.i.d. dose.

Dose (mg/kg) (𝑁≥3)	Frequency	𝐶max (μM)	AUC (μM*hr)	AUC/Dose ± SD (μM∗hr/mg/kg)
300	Once a day	10.6±2.8	167±36	0.565±0.120
600	Once a day	12.9±1.2	232±29	0.387±0.049
1000	Once a day	14.4±2.2	273±66	0.273±0.066